FDA Deep Dive Into CGMPs - Natural Products Association
FDA is intensifying CGMP enforcement for dietary supplements, with new deep-dive inspections targeting manufacturing practices. This follows recent warning letters and increased scrutiny on labeling, NDI notifications, and adulteration.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; inspections can occur without notice.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA is conducting more rigorous CGMP inspections, focusing on quality control, testing, and recordkeeping. Non-compliance may lead to warning letters, seizures, or injunctions.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers
What you must do
Review and update CGMP protocols, ensure batch testing and documentation are current, and prepare for potential FDA inspection.
Deadline
Immediately; inspections can occur without notice.
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Dietary-Supplement Labeling (FDA)
- The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls - Food and Drug Law Institute (FDLI)
- 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement - GlobeNewswire
- After 4-year review, FDA shuts down attempt to regulate CBD as a supplement and asks Congress for help - AgencyIQ by POLITICO
- US FDA New Dietary Ingredient Notification Submissions in the Last 4 Years - CIRS Group
- FDA's 2016 New Dietary Ingredient Draft Guidance - Food and Drug Law Institute (FDLI)